Skip to main content

Advertisement

Any progress for HIV vaccines to come?

Article metrics

Twenty years of HIV research has yielded vast knowledge about the immunological personality of HIV. Some of this is promising. Serendipity coupled with good experiments have taught us that seemingly antibodies of any specificity may be able to eliminate HIV infectivity in vivo provided such antibodies bind to virions with high enough avidity. Can we induce such antibodies and do they under normal conditions have to be focused on certain molecular combinations such as i.e. Gp120/CD4? Has the concept of positive auto-immunity been truly analyzed in depth? What is the present status of the concept of induction of anti-toxin antibodies as a valuable component in an HIV vaccine? Do new adjuvants provide possibilities for further enhancing the capacity of T cell immunity in animal model systems to prolong life? A suggested scheme to reach "final" answers to some of these questions will be discussed.

Author information

Correspondence to Hans Wigzell.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Keywords

  • Animal Model
  • Infectious Disease
  • Cancer Research
  • Normal Condition
  • Cell Immunity